Beta-Lactam/Beta-Lactamase Inhibitor Therapy for Potential AmpC-Producing Organisms: A Systematic Review and Meta-Analysis

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2019 Aug 1

PMID 31363762

Citations 6

Authors

Matthew P Cheng

Robyn S Lee

Alexandre P Cheng

Samuel De lEtoile-Morel

Koray Demir

Cedric P Yansouni

Patrick Harris

Emily G McDonald

Todd C Lee

Affiliations

Soon will be listed here.

Abstract

The optimal treatment for potential AmpC-producing Enterobacteriaceae, including Serratia, Providencia, Citrobacter, Enterobacter, and Morganella species, remains unknown. An updated systematic review and meta-analysis of studies comparing beta-lactam/beta-lactamase inhibitors with carbapenems in the treatment of bloodstream infections with these pathogens found no significant difference in 30-day mortality (OR, 1.13; 95% CI, 0.58 - 2.20).

Citing Articles

Advancements in Managing Choledocholithiasis and Acute Cholangitis in the Elderly: A Comprehensive Review.

Chen G, Sha Y, Wang K, Tang R, Zhai Z, Wang Z Cureus. 2025; 17(2):e78492.

PMID: 40051943 PMC: 11884421. DOI: 10.7759/cureus.78492.

Antibiotic Treatment of Infections Caused by AmpC-Producing Enterobacterales.

Tebano G, Zaghi I, Cricca M, Cristini F Pharmacy (Basel). 2024; 12(5).

PMID: 39311133 PMC: 11417830. DOI: 10.3390/pharmacy12050142.

Piperacillin/Tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations From the United States Committee on Antimicrobial Susceptibility Testing.

Lodise T, Bhavnani S, Ambrose P, Sader H, Andes D, Pogue J Clin Infect Dis. 2024; 79(6):1354-1362.

PMID: 38902929 PMC: 11650869. DOI: 10.1093/cid/ciae328.

Clinical Outcomes of Third-Generation Cephalosporin Definitive Therapy for Bloodstream Infections Due to Enterobacterales with Potential AmpC Induction: A Single-Center Retrospective Study.

Vossius G, Meex C, Moerman F, Thys M, Ernst M, Bourgeois M Pathogens. 2023; 12(9).

PMID: 37764960 PMC: 10537439. DOI: 10.3390/pathogens12091152.

Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii, Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients.

Lu B, Wong M, Ha D, Bounthavong M, Banaei N, Deresinski S J Antimicrob Chemother. 2023; 78(4):1009-1014.

PMID: 36879495 PMC: 10068414. DOI: 10.1093/jac/dkad037.

References

Lister P, Gardner V, Sanders C . Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin. Antimicrob Agents Chemother. 1999; 43(4):882-9. PMC: 89221. DOI: 10.1128/AAC.43.4.882. View

Stroup D, Berlin J, Morton S, Olkin I, Williamson G, Rennie D . Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15):2008-12. DOI: 10.1001/jama.283.15.2008. View

Chow J, Fine M, Shlaes D, Quinn J, Hooper D, Johnson M . Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991; 115(8):585-90. DOI: 10.7326/0003-4819-115-8-585. View

Qureshi Z, Paterson D, Pakstis D, Adams-Haduch J, Sandkovsky G, Sordillo E . Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections. Int J Antimicrob Agents. 2010; 37(1):26-32. DOI: 10.1016/j.ijantimicag.2010.09.009. View

Armand-Lefevre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppe E . Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother. 2013; 57(3):1488-95. PMC: 3591916. DOI: 10.1128/AAC.01823-12. View

Higgins J, Ramsay C, Reeves B, Deeks J, Shea B, Valentine J . Issues relating to study design and risk of bias when including non-randomized studies in systematic reviews on the effects of interventions. Res Synth Methods. 2015; 4(1):12-25. DOI: 10.1002/jrsm.1056. View

Harris P, Wei J, Shen A, Abdile A, Paynter S, Huxley R . Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis. J Antimicrob Chemother. 2015; 71(2):296-306. DOI: 10.1093/jac/dkv346. View

Moy S, Sharma R . Treatment Outcomes in Infections Caused by "SPICE" (Serratia, Pseudomonas, Indole-positive Proteus, Citrobacter, and Enterobacter) Organisms: Carbapenem versus Noncarbapenem Regimens. Clin Ther. 2016; 39(1):170-176. DOI: 10.1016/j.clinthera.2016.11.025. View

Noguchi T, Matsumura Y, Yamamoto M, Nagao M, Takakura S, Ichiyama S . Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study. BMC Infect Dis. 2017; 17(1):44. PMC: 5219717. DOI: 10.1186/s12879-016-2150-6. View

10.

Harris P, Peri A, Pelecanos A, Hughes C, Paterson D, Ferguson J . Risk factors for relapse or persistence of bacteraemia caused by spp.: a case-control study. Antimicrob Resist Infect Control. 2017; 6:14. PMC: 5251334. DOI: 10.1186/s13756-017-0177-0. View

11.

Cheng L, Nelson B, Mehta M, Seval N, Park S, Giddins M . Piperacillin-Tazobactam versus Other Antibacterial Agents for Treatment of Bloodstream Infections Due to AmpC β-Lactamase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2017; 61(6). PMC: 5444164. DOI: 10.1128/AAC.00276-17. View

12.

Erlanger D, Assous M, Wiener-Well Y, Yinnon A, Ben-Chetrit E . Clinical manifestations, risk factors and prognosis of patients with Morganella morganii sepsis. J Microbiol Immunol Infect. 2017; 52(3):443-448. DOI: 10.1016/j.jmii.2017.08.010. View

13.

Kohlmann R, Bahr T, Gatermann S . Species-specific mutation rates for ampC derepression in Enterobacterales with chromosomally encoded inducible AmpC β-lactamase. J Antimicrob Chemother. 2018; 73(6):1530-1536. DOI: 10.1093/jac/dky084. View

14.

Tamma P, Doi Y, Bonomo R, Johnson J, Simner P . A Primer on AmpC β-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World. Clin Infect Dis. 2019; 69(8):1446-1455. PMC: 6763639. DOI: 10.1093/cid/ciz173. View

15.

Jones R . Important and emerging beta-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol Infect Dis. 1998; 31(3):461-6. DOI: 10.1016/s0732-8893(98)00029-7. View